RAD51 and pancreatic adenocarcinoma: PAAD patients with low RAD51/MRE11/PALB2 expression and high PARP3/4 expression demonstrated a significantly poorer OS compared to PAAD patients with low RAD51/MRE11/PALB2 expression and low PARP3/4 expression (Supplementary Materials Figure S1).